Cancer DiscovJClub
Development of CAR T Cells Targeting a Surface RNA-Binding Protein for the Treatment of Acute Leukemias.
Cancer Discovery · · Journal Article · Open access
Fujino, Lewis + more
Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
CAR T cells targeting surface U5 snRNP200, an RNA helicase absent from normal hematopoietic precursors, show efficacy against AML and B-cell ALL in models.
- Why it matters: Developing CAR T cells for AML is difficult due to the lack of antigens that distinguish leukemia cells from normal hematopoietic cells, risking damage to healthy tissue.
- What they did: Researchers engineered CAR T cells based on donor autoantibodies against U5 snRNP200, a surface protein on AML cells, and armored them with IL-18 to enhance effectiveness.
- The result: These CAR T cells achieved durable remission and protection from AML rechallenge in models, suggesting a promising platform addressing tumor selectivity and safety challenges.
The findingWhy it mattersWhat they didThe result
- Open access